Results 21 to 30 of about 13,079 (188)

Bromocriptine

, 2006
europepmc   +2 more sources

Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases

American Journal of Perinatology Reports, 2018
Objective This study is to review published cases of peripartum cardiomyopathy (PPCM) treated with bromocriptine and outline pros and cons of the treatment strategy.
Rebecca Simon, Sophia Yang, Afshan B. Hameed   +2 more
doaj   +1 more source

Rapid and dramatic glucose‐lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma

Journal of Diabetes Investigation, 2021
Dopamine receptor agonists are typically used to treat Parkinson’s disease and certain pituitary tumors, such as prolactinoma or a growth hormone‐producing tumor.
Motoyuki Igata, Yoshitaka Yagi, Satoko Hanatani, Masaji Sakaguchi, Norio Ishii, Kayo Yoshinaga, Junji Kawashima, Hiroyuki Motoshima, Eiichi Araki   +8 more
doaj   +1 more source

Repurposing of Bromocriptine for Cancer Therapy

Frontiers in Pharmacology, 2018
Bromocriptine is an ergot alkaloid and dopamine D2 receptor agonist used to treat Parkinson’s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus.
Ean-Jeong Seo, Yoshikazu Sugimoto, Henry Johannes Greten, Thomas Efferth   +3 more
doaj   +1 more source

Bromocriptine in Rheumatic Diseases: A Review. [PDF]

Eur J Rheumatol
Freire de Carvalho J, Amoedo Martinez AT.   +1 more
europepmc   +2 more sources

Effects of Bromocriptine on Glucose and Insulin Dynamics in Normal and Insulin Dysregulated Horses

Frontiers in Veterinary Science, 2022
The objectives of the study were to study the effects of the synthetic ergot alkaloid (EA), bromocriptine, on glucose and lipid metabolism in insulin dysregulated (ID, n = 7) and non-ID (n = 8) mares. Horses were individually housed and fed timothy grass
Caroline M. M. Loos, Kristine L. Urschel, Eric S. Vanzant, Erin L. Oberhaus, Adam D. Bohannan, James L. Klotz, Kyle R. McLeod   +6 more
doaj   +1 more source

Bromocriptine and insulin sensitivity in lean and obese subjects

Endocrine Connections, 2016
Bromocriptine is a glucose-lowering drug, which was shown to be effective in obese subjects with insulin resistance. It is usually administered in the morning. The exact working mechanism of bromocriptine still has to be elucidated.
L Bahler, H J Verberne, E Brakema, R Tepaske, J Booij, J B Hoekstra, F Holleman   +6 more
doaj   +1 more source

Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus

Endocrinology, Diabetes & Metabolism, 2020
Objective Sympathetic nervous system (SNS) overactivity is a risk factor for insulin resistance and cardiovascular disease (CVD). We evaluated the impact of bromocriptine‐QR, a dopamine‐agonist antidiabetes medication, on elevated resting heart rate (RHR)
Bindu Chamarthi, Aaron Vinik, Michael Ezrokhi, Anthony H. Cincotta   +3 more
doaj   +1 more source

Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes

BMC Pharmacology and Toxicology, 2021
Background Dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia.
Mohammed Ahmed Fouad Shalaby, Hekma A. Abd El Latif, Mohamed El Yamani, May Ahmed Galal, Sherifa Kamal, Ikhlas Sindi, Raneem Masaood   +6 more
doaj   +1 more source

Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2

Ожирение и метаболизм, 2011
Bromocriptine is a sympatholytic agonist of dopamine receptors, which is now proposed for treatment of type 2 diabetes mellitus. In animal studies bromocriptine elevates the decreased levels of dopamine in hypothalamus and blocks excessive sympathetic ...
O. A. Gerasimenko, E. A. Pigarova, L. K. Dzeranova   +2 more
doaj   +1 more source